Expert Interview
Discussing the topline data of batoclimab in Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and how it may translate to IMVT-1402.
Ticker(s): IMVT, ROIV, ARGXInstitution: SUNY Downstate Medical Center
- Director of the Muscular Dystrophy Association Clinic and Associate Professor of Neurology at SUNY Downstate Medical Center.
- Treats 8 patients with ATTR-PN, 15 patients for Friedreich’s Ataxia and 90 patients with myasthenia gravis.
- Research Interests in HIV-related neuropathy, inflammatory myopathies and has a clinical specialty in Neuromuscular disease.
What are you currently using to treat MG?
Added By: wilson_adminWhat would a medication need to show to take market share from Vyvgart?
Added By: wilson_adminHow well do you think the data from batoclimab will translate to IMVT-1402?
Added By: wilson_adminIt looked like the baseline MG-ADL of patients in the Batoclimab data was similar to Vyvgart's ADAPT. But baseline use of steroids and NSIST's was substantially lower. Doesn't that imply that patients were less well controlled in the Batoclimab trial?
Added By: user2m293kl9Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
